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Oncogene-induced DNA methylation-mediated tran-
scriptional silencing of tumor suppressors frequently
occurs in cancer, but the mechanism and functional
role of this silencing in oncogenesis are not fully un-
derstood. Here, we show that oncogenic epidermal
growth factor receptor (EGFR) induces silencing of
multiple unrelated tumor suppressors in lung adeno-
carcinomas and glioblastomas by inhibiting the DNA
demethylase TET oncogene family member 1 (TET1)
via the C/EBPa transcription factor. After oncogenic
EGFR inhibition, TET1 binds to tumor suppressor
promoters and induces their re-expression through
active DNA demethylation. Ectopic expression of
TET1 potently inhibits lung and glioblastoma tumor
growth, and TET1 knockdown confers resistance to
EGFR inhibitors in lung cancer cells. Lung cancer
samples exhibited reduced TET1 expression or
TET1 cytoplasmic localization in the majority of
cases. Collectively, these results identify a con-
served pathway of oncogenic EGFR-induced DNA
methylation-mediated transcriptional silencing of tu-
mor suppressors that may have therapeutic benefits
for oncogenic EGFR-mediated lung cancers and
glioblastomas.INTRODUCTION
Normal cells undergo multiple genetic and epigenetic alter-
ations (DNA methylation and/or histone modification-based
modifications) to become cancerous (Baylin and Jones,
2011; Vogelstein et al., 2013), and DNA methylation-mediated
transcriptional gene silencing (hereafter referred to as epige-This is an open access article undnetic silencing) of tumor suppressor genes (TSGs) has been re-
ported in numerous cancers (Baylin and Jones, 2011; Baylin
and Ohm, 2006). Previous studies showed that oncogenes
instruct epigenetic silencing of specific TSGs and pro-
apoptotic genes (Gazin et al., 2007; Palakurthy et al., 2009;
Wajapeyee et al., 2013). Oncogenic KRAS was shown to
induce epigenetic silencing of the Fas pro-apoptotic gene via
ordered recruitment of transcriptional repressors in mouse
NIH 3T3 cells (Gazin et al., 2007; Wajapeyee et al., 2013).
Another study reported that oncogenic KRAS engages a
completely different group of proteins to induce epigenetic
silencing of TSGs in colon cancer cells, which confers the
CpG island methylator phenotype (Serra et al., 2014). Onco-
gene-induced epigenetic silencing is probably influenced by
several factors, including the oncogene type, organism and
species, and cancer type.
Epidermal growth factor receptor (EGFR) is a transmem-
brane glycoprotein and one of the four members of the erbB
family of tyrosine kinase receptors (Lurje and Lenz, 2009).
Deregulated EGFR signaling because of oncogenic mutations
in the EGFR gene or EGFR gene amplification is associated
with the genesis of numerous human cancers, including lung,
brain, breast, prostate, pancreatic, and ovarian cancer (Foley
et al., 2010; Herbst et al., 2008; Huang et al., 2009; Sheng
and Liu, 2011; Traish and Morgentaler, 2009; Troiani et al.,
2012). EGFR is mutated in a subset of lung adenocarci-
nomas, and EGFR inhibitors are now used to treat lung cancer
patients with tumors harboring EGFR mutations (Politi et al.,
2015).
Here we demonstrate that oncogenic EGFR epigenetically
silences multiple unrelated TSGs in lung cancer and glioblas-
toma multiforme (GBM) cells via transcriptional downregulation
of the active DNA demethylase TET1. We also show that TET1
exerts a tumor-suppressive effect on lung and GBM cells and
that TET1 re-expression following oncogenic EGFR inhibition is
required to elicit a response to EGFR tyrosine kinase inhibitors
(TKIs) in lung cancer.Cell Reports 16, 457–471, July 12, 2016 ª 2016 The Author(s). 457
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Oncogenic EGFR Is Necessary for Epigenetic Silencing of TSGs in Lung Cancer Cells
(A) Left: Venn diagram showing the number of genes that are commonly or specifically upregulated in HCC827/Del (DEL) or HCC827/Del-TM (DEL-TM) cells after
decitabine and vorinostat treatment. Right: heatmap of the indicated genes in HCC-827/Del (DEL) and HCC827/Del-TM (DEL-TM) cells after decitabine and
vorinostat treatment.
(BE) HCC827/Del cells were treated with gefitinib (0.1 mM), afatinib (0.1 mM), or DMSO for 48 hr.
(B) mRNA expression for the indicated TSGs was measured by qRT-PCR. Gene expression was normalized with respect to GAPDH mRNA expression. Relative
expression for the indicated genes in drug-treated cells compared with DMSO-treated cells is plotted.
(legend continued on next page)
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RESULTS
Oncogenic EGFR Induces Epigenetic Silencing of
Diverse TSGs in Lung Cancer Cells
Oncogenic EGFR is mutated in approximately 15% of lung ade-
nocarcinomas and several other cancer types (Foley et al., 2010;
Herbst et al., 2008; Huang et al., 2009). The role of oncogenic
EGFR in inducing epigenetic silencing of TSGs and its mecha-
nism of action are not known. Therefore, we investigated
whether oncogenic EGFR can induce epigenetic silencing of
TSGs in lung cancer cells, analyzed the molecular mechanism,
and evaluated the implications of EGFR-induced epigenetic
silencing of TSGs in the biology and treatment of cancer.
We tested EGFR-induced epigenetic silencing of TSGs in
EGFR mutant lung adenocarcinoma in two isogenic lung
adenocarcinoma cell lines, HCC827/Del and HCC827/Del-TM.
These cells were generated by expressing either the EGFR-
Del747-752 (Del) or EGFR-Del747-752-T790M (Del-TM) mutant
construct, respectively, in the HCC827 cell line and have been
characterized in previous studies (Costa et al., 2007; Kobayashi
et al., 2006). HCC827/Del andHCC827/Del-TMcellswere treated
with the DNA methyltransferase (DNMT) inhibitor decitabine and
the histone deacetylase inhibitor vorinostat, and changes in
gene expression were analyzed by microarray to identify genes
that were epigenetically silenced. Treatment of HCC827/Del cells
with decitabine and vorinostat altered the expression of a large
number of genes. However, only 57 genes were commonly upre-
gulated in both HCC827/Del and HCC827/Del-TM cells following
treatment with decitabine and vorinostat (Figure 1A; Table S1),
suggesting that these genes were epigenetically silenced specif-
ically bymutant EGFR. Fifteen of the 57 re-expressed geneswere
reported previously to have tumor suppressor activities in either
lung cancer or other cancer types (Table S1).
We hypothesized that the re-expressed TSGs in EGFRmutant
lung cancer cell lines treated with decitabine and vorinostat were
epigenetically silenced by oncogenic EGFR. To test this hypoth-
esis, we treated HCC827/Del and HCC827/Del-TM cells with the
EGFR inhibitor gefitinib or the second-generation EGFR inhibitor
afatinib and analyzed the expression of five unrelated TSGs
(ANGPTL4, ARNT2, ATF3, NDRG1, and NDRG4) that were re-
expressed after treatment with decitabine and vorinostat in
both HCC827/Del and HCC827/Del-TM cells (Figure S1A; Table
S1). Gefitinib treatment induced the re-expression of all five
TSGs specifically in HCC827/Del cells, whereas afatinib treat-
ment inhibited oncogenic EGFR signaling in both HCC827/Del
and HCC827/Del-TM cells and induced the re-expression of all
five TSGs in both cell lines (Figure 1B; Figure S1B). Consistent(C) DNA methylation of CpG islands in the promoters of the indicated genes was
percent of CpG island DNA methylation for the promoters of the indicated genes
(D) RNA polymerase II enrichment on TSG promoters was measured via ChIP as
treated cells.
(E) Histone H3 lysine 9 acetylation (H3K9-Ac) marks on the indicated gene promo
are shown relative to those observed in DMSO-treated cells.
(F) The indicated EGFR mutant lung cancer cell lines were treated with afatinib (0.
measured via qRT-PCR. Gene expression was normalized with respect to GAPDH
treated cells are compared with those of DMSO-treated cells.
*p < 0.05. See also Figure S1.with the re-expression of TSGs, oncogenic EGFR inhibition
reduced promoter DNA hypermethylation (Figure 1C; Fig-
ure S1C) and enrichment of RNA polymerase II (Pol II) on TSG
promoters (Figure 1D; Figure S1D), whereas oncogenic EGFR in-
hibition increased the acetylation mark of histone H3 lysine 9
(Figure 1E; Figure S1E). We generalized these results by
analyzing the expression of these five TSGs in a panel of EGFR
mutant lung cancer cell lines. Treatment of HCC827/Del and
HCC827/Del-TM cells with afatinib induced the re-expression
of all five TSGs in multiple unrelated EGFR mutant lung cancer
cell lines (Figure 1F), which provided additional support for our
hypothesis. Collectively, these results demonstrate that onco-
genic EGFR can epigenetically silence several unrelated TSGs
in multiple EGFR mutant lung cancer cell lines.
EGFR Is Sufficient to Induce Epigenetic Silencing of
TSGs in Lung Cancer Cells
We investigated whether oncogenic EGFR was sufficient to
establish epigenetic silencing of TSGs in lung cancer cells by
cloning the promoter of the tumor suppressor NDRG4 upstream
of either a firefly luciferase gene or a blasticidin resistance gene.
These constructs were stably and individually transfected into
the EGFR mutant cell line HCC827/Del and control HeLa cells.
The results indicated that the NDRG4 promoter-luciferase re-
porter and the NDRG4 promoter-blasticidin resistance gene
constructs were silenced in HCC827/Del cells but not in HeLa
cells (Figures 2A and 2B).
To confirm that oncogenic EGFR establishes the epigenetic
silencing of NDRG4 in HCC827/Del cells, we treated the cells
with a low dose of gefitinib that was sufficient to inhibit oncogenic
EGFR (Figure S1F). Gefitinib treatment stimulated luciferase ac-
tivity and increased the number of blasticidin-resistant colonies
in HCC827/Del cells but not in HeLa cells (Figures 2A and 2B).
Similar results were obtained when these cells were treated
with decitabine and vorinostat (Figure S1G) and in HCC827/Del-
TM cells treated with afatinib (Figures S1H and S1I). Consistent
with the luciferase assay results, bisulfite sequencing of the
NDRG4promoter clonedupstreamof luciferase revealed that ge-
fitinib treatment reducedCpG islandDNAmethylation (Figure2C).
Collectively, these results indicate that oncogenic EGFR is suffi-
cient to induce epigenetic silencing ofNDRG4 by increasing pro-
moter DNA methylation in lung cancer cells.
Oncogenic EGFR-Mediated Epigenetic SilencingOccurs
via MAPK Pathways
Oncogenic EGFR constitutively activates the phosphatidylinosi-
tol 3-kinase (PI3K), mitogen-activated protein kinase (MAPK),measured using methylated-DNA immunoprecipitation (Me-DIP) analysis. The
in drug-treated cells is compared with that of DMSO-treated cells.
say. Relative enrichment in drug-treated cells is compared with that of DMSO-
ters were measured. Relative amounts of H3K9-Ac marks in drug-treated cells
1 mM) or DMSO for 48 hr. mRNA expression levels for the indicated TSGs were
mRNA expression. Relative expression levels for the indicated genes in drug-
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and Janus kinase/signal transducer and activator of transcrip-
tion (JAK/STAT) pathways. To determine which pathway medi-
ates oncogenic EGFR epigenetic repression of TSGs, we used
pharmacological inhibitors to individually block each of these
three signaling pathways in HCC827/Del cells (Wortmannin
[a PI3K inhibitor], U0126 [an MEK inhibitor], or ruxolitinib
[a JAK inhibitor]). Inhibition of the PI3K or JAK pathways did
not induce re-expression of TSGs (Figures 2D and 2E). However,
inhibition of the MAPK pathway was sufficient to re-express
TSGs that were epigenetically silenced by oncogenic EGFR (Fig-
ures 2D and 2E). Consistent with these results, we observed
reduced CpG island DNA methylation (Figure 2F) and enhanced
RNA pol II enrichment (Figure 2G) on TSG promoters when the
MEK inhibitor was used. Similar results were obtained using
two different U0126 concentrations at two different time points
(Figures S2A–S2F). Collectively, these results indicate that onco-
genic EGFRmediates epigenetic silencing of TSGs by promoting
MAPK pathway activity.
Oncogenic EGFR Transcriptionally Represses the DNA
Demethylase TET1
By definition, epigenetic gene silencing is a reversible process.
Therefore, we tested whether oncogenic EGFR-mediated epige-
netic silencing of TSGs is reversible by performing an oncogenic
EGFR inhibitor washout experiment. HCC827/Del cells were
treated with gefitinib for 24 hr, gefitinib was removed by washing
cells with fresh medium lacking the drug, and samples were
collected 24 and 48 hr after drug washout. Untreated controls
and gefitinib-treated cells were included in the analysis. The re-
sults showed that gefitinib-induced inhibition of oncogenic
EGFR in HCC827/Del cells caused the re-expression of onco-
genic EGFR-repressed TSGs (Figure 3A). Consistent with the
activation of oncogenic EGFR signaling, TSGs were repressed
48 hr after drug washout (Figure 3A). TSG re-expression corre-
lated with reduced DNA methylation at CpG islands in TSG
promoters (Figure 3B). Collectively, these results indicate that
oncogenic EGFR-mediated epigenetic TSG silencing requires
continuous activity of the oncogenic EGFR pathway.
CpG island DNA demethylation can occur via passive or active
DNA demethylation (Kohli and Zhang, 2013; Pastor et al., 2013).
To distinguish between thesemechanisms, we treated HCC827/
Del cells with the DNA replication inhibitor aphidicolin in conjunc-
tion with the EGFR inhibitor gefitinib. Combined aphidicolin andFigure 2. EGFR Is Sufficient to Induce Epigenetic Silencing of TSGs an
(A) The NDRG4 promoter-luciferase reporter construct was stably transfected
indicated time points after treatment with gefitinib (0.1 mM) for 48 hr.
(B) TheNDRG4 promoter-blasticidin resistance gene construct was stably transfe
or absence of gefitinib (0.1 mM) under blasticidin selection. Representative wells
(C) Bisulfite sequencing of the NDRG4 promoter driving luciferase expression in
methylated CpGs; filled circles represent methylated CpGs.
(D and E) HCC827/Del cells were treated withWortmannin (a PI3K inhibitor, 10 mM
(D) Expression levels of the indicated proteins were analyzed via immunoblot an
(E) Expression levels of the indicated TSGs were measured via qRT-PCR. Relativ
with those of DMSO-treated cells. Gene expression was normalized with respec
(F) CpG SDIP assay. The percent of promoter CpG island DNA methylation in dr
(G) RNA Pol II recruitment was analyzed for the indicated gene promoters. The fold
cells is shown.
*p < 0.05. See also Figure S1.gefitinib treatment resulted in TSG re-expression even in the
absence of DNA replication (Figure 3C), suggesting that active
DNA demethylation is involved in this process.
Recent studies reported that TET family proteins can induce
active DNA demethylation (Kohli and Zhang, 2013; Pastor
et al., 2013). Therefore, we investigated whether TET proteins
mediated oncogenic EGFR-induced epigenetic silencing of
TSGs by measuring TET1, TET2, and TET3 expression levels in
a panel of EGFR mutant lung cancer cell lines. Afatinib inhibition
of oncogenic EGFR significantly enhanced TET1 expression in all
EGFR mutant lung cancer cell lines (Figures 3D and 3E). We as-
sessed basal levels of TET1mRNA and protein in a panel of con-
trol and EGFRmutant lung cancer cell lines. The results indicated
that TET2 and TET3 expression did not significantly differ in con-
trol and mutant cells, whereas TET1 expression was generally
lower in EGFR mutant cells than in wild-type EGFR lung cancer
cell lines (Figure 3F). Additional control experiments measuring
the expression of TET2, TET3, and DNMTs did not detect any
significant differences in the expression of these genes in
response to inhibition of oncogenic EGFR signaling (Figures
S2G and S2H). Similar results were obtained using immortalized
human airway epithelial cells (HAE/SV40-ER+hTERT) expressing
either the EGFR Del mutant (EGFR-Del747-752) alone or the
EGFR-Del and T790M mutants (EGFR-Del747-752+T790M)
(Figure S3). These results further confirm a role for oncogenic
EGFR signaling in epigenetic silencing of TSGs.
EGFR Regulates TET1 Expression via the C/EBPa
Transcription Factor
To determine the mechanism of TET1 upregulation following
oncogenic EGFR inhibition, we analyzed the TET1 promoter
sequence and identified potential DNA binding sites for several
transcription factors (TFs) (Table S2). To determine which of
these TFs regulate TET1 transcription after oncogenic EGFR
inhibition, we checked the expression of these TFs in a panel
of EGFR mutant lung cancer cell lines after treatment with afati-
nib. Oncogenic EGFR inhibition induced the expression of
GATA2, C/EBPa, and C/EBPb in five out of six EGFR mutant
lung cancer cell lines (Figure 4A; Figure S4A), which correlated
with the TET1 re-expression pattern in these EGFR mutant
lung cancer cells.
To determine which TFs regulate TET1 transcription, we
knocked down the expression of each TF using smallhairpind Inhibits Expression of TSGs via the MAPK Pathway
into HCC827/Del or HeLa cells, and luciferase activity was measured at the
cted into HCC827/Del or HeLa cells, and colonies were formed in the presence
are shown.
HCC827/Del cells under the indicated conditions. Open circles represent un-
), U0126 (aMEK inhibitor, 10 mM), or ruxolitinib (a JAK inhibitor, 10 mM) for 48 hr.
alyses.
e expression levels for the indicated TSGs in drug-treated cells are compared
t to GAPDH mRNA expression.
ug-treated cells was compared with that observed in DMSO-treated cells.
enrichment of RNA Pol II in drug-treated cells relative to that in DMSO-treated
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Figure 3. EGFR Transcriptionally Represses the Active DNA Demethylase TET1
(A and B) HCC827/Del cells were treated with gefitinib (0.1 mM) for 48 hr and then washed out. DMSO-treated samples, gefitinib-treated samples, and samples
harvested 24 and 48 hr after washout of gefitinib were collected.
(A) Samples were analyzed for the indicated proteins via immunoblot analyses (left) or for the transcripts of the indicated TSGs via qRT-PCR (right).
(B) DNAmethylation of the CpG islands in the promoters for the indicated TSGs were analyzed via Me-DIP analyses. The percent of CpG island DNAmethylation
for HCC827/Del cells under the indicated conditions relative to that of DMSO-treated cells is shown.
(C) HCC827/Del cells were treated with aphidicolin (5 mM) and gefitinib (0.1 mM) for 48 hr, and the expression levels of the indicated TSGs were analyzed via qRT-
PCR. Relative mRNA expression levels for the indicated TSGs in drug-treated cells were compared with those in DMSO-treated cells.
(D) The indicated EGFRmutant lung cancer cell lines were treated with afatinib, and the expression of TET1mRNAwasmeasured via qRT-PCR. Gene expression
was normalized with respect to GAPDH mRNA expression.
(legend continued on next page)
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RNAs (shRNAs) (Figure 4B; Figures S4B and S4C). We found
that C/EBPa knockdown blocked TET1 re-expression after
oncogenic EGFR inhibition (Figure 4B), whereas GATA2 and
C/EBPb knockdown did not affect TET1 expression (Figure S4D).
Similar results were obtained in other EGFR mutant lung cancer
cell lines (Figure S4E).
To confirm that C/EBPa directly regulates TET1 expression,
we performed a chromatin immunoprecipitation (ChIP) experi-
ment. The ChIP results showed that C/EBPa directly bound to
the TET1 promoter after EGFR signaling inhibition (Figure 4C).
Next we determined the mechanism of oncogenic EGFR
pathway inhibition upregulation of C/EBPa by analyzing the
C/EBPa promoter sequence and identifying several TF binding
sites. We selected YY1 for further analysis because it repressed
transcription (Gordon et al., 2006) and was previously reported
to be regulated by the MAP kinase pathway (Stoeckius et al.,
2012). We tested whether YY1 was regulated by EGFR in a
MAP kinase pathway-dependent manner in EGFR mutant lung
cancer cells. The results showed that treatment of HCC827/
DEL cells with afatinib or U0126 reduced the YY1 protein level
(Figure S4F) and that YY1 knockdown upregulated C/EBPa
(Figure S4G). We also performed a ChIP assays to test whether
YY1 directly repressed C/EBPa expression. We found that YY1
was enriched on the C/EBPa promoter in HCC827/Del cells,
which was inhibited by treatment with afatinib or U0126 (Fig-
ure S4H). Collectively, these results indicate that oncogenic
EGFR pathway inhibition upregulates the C/EBPa TF via YY1,
which, in turn, stimulates the expression of the active DNA de-
methylase TET1.
TET1 Upregulation after Oncogenic EGFR Signaling
Inhibition Is Necessary for TSG Re-expression
We also evaluated the functional association between TET1
upregulation and TSG re-expression after oncogenic EGFR inhi-
bition. We found that shRNA-induced TET1 knockdown pre-
vented re-expression of repressed TSGs after afatinib treatment
(Figures 4D and 4E). Similar to afatinib treatment, U0126 was
able to re-express C/EBPa (Figures S5A and S5B). However,
ectopic expression of oncogenic KRASG12D prevented afati-
nib-induced C/EBPa and TSG re-expression (Figures S5C and
S5D). Collectively, these results indicate that TET1 activation is
required for TSG re-expression after oncogenic EGFR pathway
inhibition.
TET1 catalyzes the hydroxylation of 5-methyl cytosine (5mC)
to 5-hydroxymethyl cytosine (5hmC) and thereby facilitates
active DNA demethylation (Pastor et al., 2013). Therefore, we
analyzed TET1 enrichment on TSG promoters by performing a
ChIP analysis. We found that TET1 proteins were significantly
enriched on TSG promoters in afatinib-treated HCC827/Del cells
(Figure 4F). Collectively, these results indicate that TET1 re-
expression after oncogenic EGFR signaling inhibition is neces-
sary for TSG re-expression in EGFR mutant lung cancer cells.(E) The indicated EGFRmutant lung cancer cell lines were treated with afatinib, an
immunoblot analyses. GAPDH expression was used as a loading control.
(F) The indicated lung cancer cell lines were analyzed for TET1 expression via qRT
shown.
*p < 0.05. See also Figure S2.Oncogenic EGFR-Mediated Epigenetic Silencing of
TSGs Is Conserved in GBM Cells
Oncogenic EGFR mutations are known to be present in GBM
cells (Furnari et al., 2015). Therefore, we analyzed the mecha-
nism of TSG silencing in GBM cells. We used an isogenic GBM
cell line that was generated by ectopic expression of the
EGFRvIII mutation in U87 cells (U87/EGFRvIII) and analyzed
TET1 expression in U87 and U87/EGFRvIII cells. Ectopic expres-
sion of EGFRvIII in U87 cells repressed TET1 expression (Fig-
ure 5A) in an oncogenic EGFR-dependent manner; gefitinib
treatment of U87/EGFRvIII cells and two patient-derived xeno-
graft GBM cell lines (GBM6 and GBM313) resulted in TET1 re-
expression (Figures 5B and 5C). Similar results were obtained
using the MEK inhibitor U0126 (Figure S5E). Collectively, these
results indicate that TET1 is regulated by MAP kinase pathway
activity in U87/EGFRvIII and additional GBM cell lines.
We then analyzed the expression of five TSGs (ANGPTL4,
ARNT2, ATF3, NDRG1, and NDRG4) that were tested in lung
cancer cells to determine whether oncogenic EGFR epigeneti-
cally repressed TSG expression in GBM cells. We found that
oncogenic EGFR inhibition was sufficient to induce re-expres-
sion of four of these TSGs (Figures 5D and 5E). Consistent with
epigenetic TSG silencing, we also found that the TSG re-expres-
sion correlated with reduced CpG island methylation in TSG
promoters (Figure 5F). TET1 knockdown in U87/EGFRvIII cells
prevented TSG re-expression after gefitinib treatment (Fig-
ure 5G). Collectively, these results indicate that oncogenic
EGFR epigenetically represses the same TSGs in different tumor
types via a conserved TET1-dependent mechanism.
TET1 Expression Is Necessary for EGFR Mutant Lung
Cancer Cell Response to EGFR Inhibitors
Previous studies reported that TET1 can function as a tumor sup-
pressor (Cimmino et al., 2015; Neri et al., 2015). Therefore, we
analyzed whether TET1 repression was necessary for tumor for-
mation in EGFR mutant lung cancers and glioblastomas by
ectopically expressing TET1 in lung cancer and GBM cell lines.
We found that ectopic expression of TET1 reduced tumor growth
in soft agar assays, indicating that tumor growth was inhibited
(Figure 6A), and significantly reduced tumor formation in athymic
nude mice (Figure 6B). To confirm these in vivo results, we eval-
uated the effect of TET1 expression in a patient-derived xeno-
graft (PDX) of EGFRmutant lung adenocarcinoma. EGFRmutant
lung cancer PDX-bearing mice were intratumorally injected with
either a control adenovirus expressing GFP or an adenovirus ex-
pressing TET1 (Ad-TET1) every 3 days for 2 weeks. Ectopic
expression of TET1 in this EGFR mutant lung cancer PDX model
inhibited tumor growth in vivo (Figure 6C).
EGFR represses TET1 expression, so we evaluated whether
TET1 played a role in determining the response to EGFR
inhibitors by knockdown of TET1 expression in EGFR mutant
cell lines treated with gefitinib. Loss of TET1 in the EGFR mutantd the expression levels of TET1 and other indicated proteins were measured via
-PCR. TET1 expression in lung cancer cell lines relative to that of MRC5 cells is
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Figure 4. EGFR Regulates TET1 Expression via the Transcription Factor C/EBPa
(A) The indicated lung cancer cell lines were treated with afatinib (0.1 mM) for 48 hr, and themRNA and protein expression levels of the transcription factor C/EBPa
were analyzed via qRT-PCR (left) or immunoblot analysis (right), respectively.
(B) The HCC827/Del cell line expressingC/EBPa or non-specific (NS) shRNAswas treatedwith afatinib (0.1 mM) for 48 hr and analyzed for TET1mRNA expression
or TET1 protein expression via qRT-PCR (left) or immunoblot analysis (right), respectively.
(legend continued on next page)
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HCC827/Del andH3255 lines increased cellular resistance to ge-
fitinib (Figures 6D and 6E; Figures S5F and S5G). Next we eval-
uated whether this mechanism of resistance operated in vivo by
analyzing tumor samples derived from a previously described
EGFR-driven mouse model of lung tumorigenesis (Politi et al.,
2006). Specifically, we compared normal lung samples with
lung tumor samples that were either left untreated, treated for
5 days with erlotinib and presumed to be responding to the
drug (erlotinib-responsive), or had acquired resistance to erloti-
nib (erlotinib-resistant). Consistent with our cell culture studies,
erlotinib-responsive lung tumors exhibited increased TET1
expression whereas erlotinib-resistant lung tumors did not (Fig-
ure 7A). TET1 expression was inversely correlated with MAP ki-
nase target gene expression, and erlotinib-resistant samples
continued to display higher MAP kinase target gene expression
(Figure S6A).
We analyzed these samples further to determine whether
TET1 expression correlated with overall 5hmC marks. Consis-
tent with our TET1 expression results, we found that erlotinib-
responsive samples exhibited higher levels of 5hmC marks
compared with those of erlotinib-resistant samples (Figure 7B).
We also analyzed patient-derived samples of lung cancers with
various genotypes (36 KRAS mutants, 27 EGFR mutants, and
53 KRAS/EGFR wild-type samples). TET1 was significantly inac-
tivated in all genotypes (Figure 7B). For example,44% of EGFR
mutant lung cancers were negative for TET1 expression,
whereas 44% showed cytoplasmic localization of TET1, and
only 11% showed both cytoplasmic and nuclear localization of
TET1 (Figure 7C). These results demonstrate that a large per-
centage of lung cancer samples display TET1 inactivation in pa-
tient-derived lung cancer samples.
We tested whether TET1 inactivation correlated with EGFR
TKI resistance by analyzing six EGFR TKI-sensitive and seven
EGFR TKI-resistant human lung cancer samples. Our results
show that, although none of the EGFR TKI-resistant tumors ex-
pressed TET1 (0 of 7, 0%), half of the EGFR TKI-sensitive
samples exhibited nuclear TET1 staining (3 of 6, 50%). These
results further support a role for TET1 in modulating the
response to EGFR TKIs in lung cancer cells (Figure 7D; Fig-
ure S6B). We also analyzed the expression of several tumor
suppressor genes in publicly available datasets and observed
a significant association of reduced TSG expression with over-
all reduced survival in lung cancer patients (Figure S7). Collec-
tively, our data provide evidence that TET1 functions as a tumor
suppressor in lung cancer and GBM cells and that oncogenic
EGFR inhibition-induced TET1 activation may be necessary
for a cellular response to EGFR inhibitors (Figure 7E). Therefore,
future analysis using a larger cohort of lung cancer samples will
be important for further establishing the utility of TET1 expres-
sion as a possible biomarker for predicting responses to EGFR
inhibitors.(C) The HCC827/Del cell line was treated with afatinib (0.1 mM) for 48 hr, and the o
enrichment of C/EBPa in afatinib-treated cells was compared with that of an IgG
(D and E) HCC827/Del cells expressing TET1 or NS shRNAs were treated with afa
protein levels via qRT-PCR (D) and immunoblot analysis (E), respectively.
(F) HCC827/Del cells were treated with afatinib (0.1 mM) for 48 hr and analyzed f
*p < 0.05 and **p < 0.005. See also Figures S3 and S4.DISCUSSION
Our results allow us to draw several important conclusions. First,
we found that oncogenic EGFR epigenetically silenced several
unrelated TSGs in lung cancer and GBM cells via a conserved
mechanism that involved transcriptional repression of the active
DNA demethylase TET1. Second, we determined that oncogenic
EGFR-induced epigenetic silencing was rapid and reversible;
therefore, it was not truly epigenetic because it required contin-
uous activity of the oncogenic EGFR pathway. Third, we showed
that ectopic TET1 expression induced tumor-suppressive ef-
fects in lung cancer and GBM cells and that TET1 expression
was necessary to elicit responses to EGFR TKIs in lung cancer
cells. Finally, our study documented a non-redundant function
of the TET1 protein within the context of TSG epigenetic
silencing. TET1 was necessary for oncogenic EGFR-induced
epigenetic gene silencing but TET2 and TET3 were not.
Oncogenic EGFR-Mediated Epigenetic Silencing
of TSGs
Previous studies have established the importance of epigenetic
alterations in cancer initiation and progression. Genome-wide
andexome-widecancer sequencingprojects identifiedmutations
in genes encoding proteins that regulate either DNA methylation
or post-translational histone modifications (Huether et al., 2014).
Collectively, these results indicate that the cancer epigenome
can induce alterations in human cancers, similar to the cancer
genome. However, it is not fully understood whether genetic
andepigenetic alterations incancer cells emergeandevolve inde-
pendently or cooperatively. It is also not knownwhether an onco-
gene can direct the epigenetic silencing of a group of TSGs or the
mechanism by which this epigenetic silencing may occur.
Here we report that oncogenic EGFR can instruct the epige-
netic silencing of multiple unrelated TSGs in lung cancer and
GBM cells. The observed epigenetic silencing was rapidly
reversed and re-established, and so it does not represent a
true epigenetic event that self-propagates when established.
We find that continuous activity of oncogenic EGFR is required
to maintain TSG silencing.
Our results are consistent with those of a previous study of
oncogenic KRAS. However, those studies were performed in
mouse cells, and the implications of those results in human can-
cer are unclear (Gazin et al., 2007; Wajapeyee et al., 2013). Our
study extends these initial findings and identifies an instructive
pathway for epigenetic silencing of TSGs in human lung cancer
and GBM cells.
The Role of TET1 in Oncogenic EGFR-Induced TSG
Silencing
Epigenetic silencing can be reversed by passive DNA demethy-
lation that involves DNA replication or active DNA demethylationccupancy of C/EBPa on the TET1 promoter was analyzed via ChIP. The relative
control is shown at two predicted C/EBPa.
tinib (0.1 mM) for 48 hr and analyzed for TET1 expression and TSG mRNA and
or TET1 occupancy on the promoters of the indicated TSGs via ChIP.
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Figure 5. EGFR-Driven TET1 Repression Is Conserved in EGFR Mutant GBM
(A) The mRNA expression level of TET1 was measured via qRT-PCR. Relative TET1 mRNA levels in U87/EGFRvIII cells were compared with those in U87 cells
(left). The TET1 protein expression level was measured via immunoblot analysis. TET1 and GAPDH expression in U87/EGFRvIII cells was compared with that in
U87 cells (right).
(B) The indicated GBM cells were treated with the indicated gefitinib concentrations for 48 hr and analyzed for TET1mRNA expression via qRT-PCR. The relative
mRNA expression levels for TET1 and the indicated TSGs in drug-treated cells were compared with those in DMSO-treated GBM cells.
(C) The indicated GBM cells were treated with the indicated gefitinib concentrations for 48 hr and analyzed for TET1 expression level via immunoblotting. GAPDH
expression was used as an internal control.
(D) U87/EGFRvIII cells were treatedwith gefitinib (10 mM) and analyzed for the expression of the indicated TSGs via qRT-PCR. The relative expression levels of the
TSGs in U87/EGFRvIII cells were compared with those in DMSO-treated cells.
(E) U87/EGFRvIII cells were treated with DMSO or gefitinib (10 mM) for 48 hr and analyzed for the expression of TET1 and the indicated TSG proteins via
immunoblot analyses.
(legend continued on next page)
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that occurs without DNA replication. Several proteins have been
implicated in active DNA demethylation, such as TET family pro-
teins and the DNA repair enzymes TDG and AID, which mediate
the enzymatic conversion of 5mC to cytosine (Pastor et al.,
2013).
Here we found that oncogenic EGFR transcriptionally re-
presses TET1, which is necessary for oncogenic EGFR-medi-
ated epigenetic silencing of TSGs in distinct tumor types such
as lung cancer andGBM. TET1 repression is necessary for onco-
genic EGFR-induced epigenetic TSG silencing. The results sug-
gest that TET proteins have non-redundant functions because
TET1 repression was necessary for epigenetic silencing of
TSGs but TET2 and TET3 repression was not. Collectively, these
results show that oncogenic EGFR represses TET1, which en-
ables epigenetic silencing of TSGs.
TET Regulates EGFR-Induced Tumor Growth and
Cellular Response to EGFR Inhibitors
Previous studies show that TET proteins play an important role in
cancer; reduced expression of TET1, TET2, and TET3 is associ-
ated with poor prognoses for patients with early-stage breast
cancer (Yang et al., 2015). TET1 has tumor-suppressive activity
in colon, breast, and gastric cancers (Fu et al., 2014; Lu et al.,
2014; Neri et al., 2015; Sun et al., 2013). Here we show that
TET1 expression in lung cancer andGBMcells inhibits tumor for-
mation, indicating that TET1 confers tumor-suppressive activity
in lung cancer. We detected the loss of TET1 expression and
mislocalized cytoplasmic TET1 in many patient-derived lung
cancer samples, suggesting that TET1 was likely inhibited.
Our study suggests that TET1 determines the response to
EGFR TKIs because the loss of TET1 expression confers resis-
tance to EGFR TKIs. Collectively, these results demonstrate
that oncogenic EGFR-mediated epigenetic silencing and regula-
tion of DNA demethylase is central to the role of EGFR as an
oncogene and determines the cellular response to EGFR TKIs.
EXPERIMENTAL PROCEDURES
Gene Expression Profiling and Data Analysis
The HCC827/Del and HCC827/Del-T790M cell lines were treated with DMSO,
decitabine (2.5 mM), vorinostat (1 mM), or a combination of both decitabine and
vorinostat for 72 hr. Total RNA was prepared from three biological replicates
for each sample using TRIzol (Invitrogen) and purified with the QIAGEN RNA
easy kit. For hybridization, cDNA was prepared using the Illumina TotalPrep
RNA amplification kit according to the manufacturer’s protocols. Then cDNA
was hybridized to a HumanHT-12 v4 Expression BeadChip, which was
scanned and analyzed using an Illumina’s HiScan machine.
Microarray data were generated by GenomeStudio (Illumina), log2-trans-
formed, and quantile-normalized using ArrayStudio (Omicsoft). Quality control
(QC) was performed by checking various plots as in general microarray anal-
ysis methods. All samples passed QC. Differential expression analysis was
performed using a one-way analysis of variance test with a Benjamini and
Hochberg multiple test correction procedure to identify statistically significant
differentially expressed probes (adjusted p value% 0.05). Pathway enrichment(F) U87/EGFRvIII cells were treatedwith gefitinib and analyzed for DNAmethylatio
DNA methylation levels for the indicated TSGs in drug-treated cells were compa
(G) U87/EGFRvIII cells expressing either a non-specific shRNA or shRNAs target
the indicated genes via qRT-PCR.
*p < 0.05 and **p < 0.005. See also Figure S5.analysis was performed for an input gene list (absolute fold change R 2 and
significant adjusted p value % 0.05) using MetaCore (version 6.8, build
29806, GeneGo).
Drug Treatments
Cells were treated with the indicated concentrations of gefitinib, afatinib, aphi-
dicolin, decitabine, and vorinostat (Table S3). For the aphidicolin experiment,
cells were treated with EGFR inhibitor along with aphidicolin. In each case,
cells were collected for RNA extraction 48 hr after treatment. For EGFR inhib-
itor washout experiments, HCC827/Del cells were treated with gefitinib. Gefi-
tinib was removed after 24 hr of treatment, and cells were washed twice with
PBS before suspension in fresh medium. For the experiments, cells were
collected at the indicated time points after washout.
Soft Agar, Tumor Xenograft, and Patient-Derived Xenograft
Experiments
Soft agar assays were performed as described previously (Gazin et al., 2007).
For in vivo experiments, the HCC827/Del, PC9, H3255, and U87/EGFRvIII cell
lines expressing either an empty vector or TET1 were injected subcutaneously
into the flanks of nude mice (n = 10). Tumors were allowed to grow, and tumor
growth was monitored every week. Tumor volume was calculated using the
formula volume = length 3 width2 3 0.5, and average tumor volumes were
plotted. For the PDX experiments, we obtained 15 non-obese diabetic/severe
combined immunodeficiency (NOD/SCID) mice bearing EGFRmutant (L858R)
PDX (model TM00199) from Jackson Laboratory. Mice were assigned to three
groups of five mice each, and after the average tumor volume reached
100mm, tumors were injected with 50 ml (titer = 13 1011) of control adenovirus
(Ad-LacZ) or TET1 adenovirus (Ad-TET1).
EGFR Mouse Tumor Samples
Mice were bred and housed in a pathogen-free environment under guidelines
approved by the Yale University Institutional Animal Care and Use Committee
(IACUC). CCSP-rtTA; TetO-EGFRL858R mice were described previously (Politi
et al., 2006). Doxycycline was administered by feeding mice with doxycycline-
impregnated food pellets (625 ppm, Harlan-Tekland). Erlotinib (Organic Syn-
thesis Core Facility of Memorial Sloan Kettering Cancer Center [MSKCC])
was suspended in 0.5% (w/v) methylcellulose and administered intraperitone-
ally, 25 mg/kg, 5 days a week. Mice bearing untreated tumors, tumors treated
for 5 days (erlotinib-responsive), or erlotinib-resistant tumors (CCSP-rtTA;
TetO-EGFRL858R) were enrolled in the study. Erlotinib resistance was assessed
by continuous or intermittent drug treatment as described previously (Pirazzoli
et al., 2016). For molecular studies, freshly harvested tumors and adjacent
normal lung tissue were pulverized in liquid nitrogen. RNA was extracted using
the RNeasy platform (QIAGEN) and then treated with DNase I (RNase-Free
DNA set, QIAGEN). Genomic DNA was extracted using the Wizard genomic
purification kit (Promega).
Tissue Microarray Analysis, EGFR TKI-Sensitive and TKI-Resistant
Patient Sample Analysis, and TET1 Staining Protocol
Yale tissue microarray (YTMA) 310 contains 139 tumor cores from a non-serial
collection of non-small-cell lung cancer (NSCLC) patients with different muta-
tion status. For YTMA 310 construction, pathology reports from 20112013
were retrieved. NSCLC patient cases that had surgical resection of the primary
tumor and molecular testing for common NSCLC mutations were selected for
further review. The cases that had adequate residual tumor from the primary
site were collected and cored. YTMA 310 includes 30 EGFR mutants, 43
KRAS mutants, and 66 non-mutant EGFR and KRAS patient cases.
Six EGFR TKI-sensitive and seven EGFR TKI-resistant samples from either
the patients or the patient-derived xenografts were analyzed for TET1n at CpG islands in the promoters of the indicated TSGs viaMe-DIP. The relative
red with those observed in U87/EGFRvIII cells treated with DMSO.
ing TET1 were treated with gefitinib (10 mM) and analyzed for the expression of
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Figure 6. TET1 Confers Tumor-Suppressive Activity in Lung Cancer and GBM Cells and Is Necessary for the Response to EGFR TKIs
(A) Left: the indicated lung cancer and GBM cell lines expressing either empty vector or TET1 were grown on soft agar. Representative wells are shown. Right:
relative colony sizes for the indicated lung cancer and GBM cell lines are shown.
(B) The indicated lung cancer and GBM cell lines expressing either empty vector or TET1 were injected into athymic nude mice. Average tumor volumes for the
indicated conditions are shown at the indicated time points.
(C) EGFR mutant lung cancer PDX-bearing mice were injected with either a control (Ad-LacZ) or TET1 (Ad-TET1) adenovirus. Average tumor volumes for the
indicated conditions are shown at the indicated time points.
(D) HCC827/Del cells expressing either TET1 or non-specific shRNAs were treated with gefitinib (0.1 mM). The relative percent of cell viability and the percent of
annexin V-positive cells of the indicated cell lines expressing TET1 shRNA relative to cells expressing NS shRNAs are shown after 48 hr of treatment.
(E) H3255 cells expressing either TET1 or NS shRNAswere treated with gefitinib (0.1 mM). The percent of cell viability and the percent of annexin V-positive cells of
the indicated cell lines expressing TET1 shRNA relative to that of cells expressing NS shRNAs are shown after 48 hr of treatment.
*p < 0.05. See also Figure S5.
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Figure 7. TET1 Is Downregulated or Mislocalized in Lung Cancer Samples and EGFR TKI-Resistant Samples
(A) Normal lung samples, EGFR-driven untreated lung cancer samples, and EGFR-driven erlotinib-treated lung cancer samples that were either sensitive or
resistant to erlotinib treatment were analyzed for TET1 mRNA expression. The relative TET1 expression is shown.
(B) Erlotinib-sensitive or erlotinib-resistant lung tumor samples were used to isolate genomic DNA, and the number of 5hmC marks was evaluated by dot blot
analyses of 100 ng genomic DNA (left). The membrane was then stained with methylene blue to confirm equal DNA loading (right).
(C) Analysis of patient-derived lung cancer samples shows the loss of TET1 expression and the cytoplasmic localization of TET1, indicating that TET1 expression
is reduced in lung cancer. Left: representative images for EGFR mutant lung cancers and the percent of samples across three genotypes with no staining,
cytoplasmic staining, or cytoplasmic and nuclear staining are shown. Right: summary of the IHC results.
(D) Top: representative images for lung cancer samples stained for TET1. Bottom: summary of the IHC results.
(legend continued on next page)
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expression using TET1 immunohistochemistry (IHC). All samples selected for
this analysis lacked the EGFR T790M mutation. TET1 antibody was used at
1:1,000 dilution for the IHC experiments, and the antigen was retrieved using
sodium citrate buffer (pH = 6.0). Secondary anti-rabbit horseradish peroxidase
(HRP)-conjugated antibody (Envision+ system, HRP-labeled polymer anti-
rabbit) was obtained from DAKO. The slides were developed using the liquid
DAB+ substrate chromogen system from Dako.
Statistical Analyses
All experiments were performed at least three times, and data were expressed
as the mean ± SE. The area under the curve (AUC) values were calculated us-
ing GraphPad Prism version 6.02 for Macintosh (GraphPad). The p values were
computed with Student’s t test in Microsoft Excel.ACCESSION NUMBERS
The accession number for the gene expression data reported in this paper is
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